Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-143165

Published: 2020

Journal Articles

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134327

Published: 2020

Journal Articles

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Heidi Altmann, PhD, Sarah E. Church, PhD, Hanna A Knaus, MD, Mark D. Minden, Jan K Davidson-Moncada, MDPhD, Sarah K Tasian, MD, Martin Bornhäuser, MD, Ivana Gojo, MD, Leo Luznik, MD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134779

Published: 2020

Journal Articles

Reducing Dependence on General Anesthesia for Pediatric Oncology Outpatients Undergoing Repeated Lumbar Punctures

Esther R. Berko, MD, Yahui Wei, Emily Stiglich, Derek Klingman, Julie Vardaro, Sarah K Tasian, MD, Sara McDonough, CRNP, Katelyn Oranges, CRNP, Kelly Meyers, CRNP, Eileen Aber, CRNP, Miriam Kolb, CRNP, Lindsay Borel, Nicholas Evageliou, MD, Rebecca Citrin, MD, Jane Minturn, MD PhD, Anne Reilly, MD, Susan R. Rheingold, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-143153

Published: 2020

Journal Articles

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Martin P. Carroll, MD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, MDPhD, Sung June Lee, BA, Anil Kumar, PhD, Anne Lehman, Joseph Patrick Loftus, BS, Grace Jeschke, PhD, John D. Crispino, PhD, Thierry Besson, PhD, Junwei Shi, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141258

Published: 2020

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Journal Articles

Glucocorticoids Regulate the Splicing Factor MBNL1, a Potential Control Point for B-Cell Specification

Miles A. Pufall, PhD, Mimi Fang, Robert K. Bradley, PhD, Chew Guo-Liang, Ross Lanier, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 2478.

https://doi.org/10.1182/blood-2019-131322

Published: 2019

Journal Articles

PI3Kδ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy

Jessica A.O. Zimmerman, MD, Mimi Fang, Arunkumar Modi, MBBS, MPH, Adam Dupuy, PhD, Sarah K. Tasian, MD, Miles A. Pufall, PhD

Blood (2019) 134 (Supplement_1): 2572.

https://doi.org/10.1182/blood-2019-129205

Published: 2019

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Sarah K. Tasian, MD, Albert Assad, MD, Deborah S Hunter, PhD, Yining Du, PhD, Mignon L. Loh, MD

Blood (2018) 132 (Supplement 1): 555.

https://doi.org/10.1182/blood-2018-99-110221

Published: 2018

Journal Articles

Immunophenotypic and Genetic Overlap between JMML and CMML

Cody E. Cotner, BA, Mitul Modi, MBBS, MD, Gerald Wertheim, MD, PhD, Michele Paessler, D.O., Sarah K. Tasian, MD, Minjie Luo, PhD, Vinodh Pillai, MD, PhD

Blood (2018) 132 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2018-99-116730

Published: 2018

Journal Articles

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Bruce Ruggeri, Matthew C. Stubbs, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2017) 130 (Supplement 1): 717.

https://doi.org/10.1182/blood.V130.Suppl_1.717.717

Published: 2017

Journal Articles

Enhanced Efficacy of the SYK Inhibitor Entospletinib and Chemotherapy in Infant Acute Lymphoblastic Leukemia

Joseph Patrick Loftus, BS, Anella Yahiaoui, BS, Feng Shen, MDPhD, David Lopez, Igor Mikaelian, DVM, Patrick A Brown, MD, Stacey Tannheimer, PhD, Ann Forslund, PhD, Sarah K Tasian, MD

Blood (2017) 130 (Supplement 1): 2611.

https://doi.org/10.1182/blood.V130.Suppl_1.2611.2611

Published: 2017

Journal Articles

Immune Gene Expression Profiling in Children and Adults with Acute Myeloid Leukemia Identifies Distinct Phenotypic Patterns

Jayakumar Vadakekolathu, PhD, Tasleema Patel, BSc, Stephen Reeder, BSc, Heidi Schaarschmidt, BSc, Marc Schmitz, MD, Martin Bornhäuser, MD, Sarah E. Warren, PhD, Tressa Hood, MS, Patrick Danaher, PhD, Alessandra Cesano, Joseph M. Beechem, PhD, A. Graham Pockley, PhD, Sarah K Tasian, MD, Sergio Rutella, MDPhDFRCPath

Blood (2017) 130 (Supplement 1): 3942.

https://doi.org/10.1182/blood.V130.Suppl_1.3942.3942

Published: 2017

Journal Articles

Mutation-Specific Signaling Profiles and Therapeutic Vulnerabilities of Induced Pluripotent Stem Cell Models of Juvenile Myelomonocytic Leukemia

Sarah K Tasian, MD, Jessica A Casas, MD MPH, David Posocco, Shilpa Gandre-Babbe, Alyssa Gagne, Ge Liang, Mignon L. Loh, MD, Mitchell J Weiss, MD PhD, Deborah L French, PhD, Stella T Chou, MD

Blood (2017) 130 (Supplement 1): 1678.

https://doi.org/10.1182/blood.V130.Suppl_1.1678.1678

Published: 2017

Journal Articles

Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD PhD, Rachel Astles, BA, Alexis Zebrowski, BA, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2016) 128 (22): 755.

https://doi.org/10.1182/blood.V128.22.755.755

Published: 2016

Journal Articles

Evaluating on-Target Toxicity of Hematopoietic-Targeting Cars Demonstrates Target-Nonspecific Suppression of Marrow Progenitors

Christopher Tor Sauter, BA, Christopher Daniel Chien, PhD, Feng Shen, MD PhD, Sarah K Tasian, MD, Terry J Fry, MD

Blood (2016) 128 (22): 3357.

https://doi.org/10.1182/blood.V128.22.3357.3357

Published: 2016

NARROW

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

Reducing Dependence on General Anesthesia for Pediatric Oncology Outpatients Undergoing Repeated Lumbar Punctures

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Glucocorticoids Regulate the Splicing Factor MBNL1, a Potential Control Point for B-Cell Specification

PI3Kδ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Immunophenotypic and Genetic Overlap between JMML and CMML

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Enhanced Efficacy of the SYK Inhibitor Entospletinib and Chemotherapy in Infant Acute Lymphoblastic Leukemia

Immune Gene Expression Profiling in Children and Adults with Acute Myeloid Leukemia Identifies Distinct Phenotypic Patterns

Mutation-Specific Signaling Profiles and Therapeutic Vulnerabilities of Induced Pluripotent Stem Cell Models of Juvenile Myelomonocytic Leukemia

Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL

Evaluating on-Target Toxicity of Hematopoietic-Targeting Cars Demonstrates Target-Nonspecific Suppression of Marrow Progenitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only